What is the effect of Humacology (Cannabidiol/CBD + Cannabinol/CBN + Cannabichromene/CBC) 'BLACK' oil with a concentration of 0:250:60:20 on the human body?

From the Guidelines

Humacology "BLACK" 0:250:60:20 is a broad-spectrum CBD oil product that may be beneficial for those seeking relief from anxiety, insomnia, or pain without the psychoactive effects of THC, but its use should be approached with caution due to potential risks and interactions, as noted in the 2024 ASCO guideline 1. The product contains a blend of cannabinoids including CBD (250mg), CBN (60mg), and CBC (20mg) per bottle, without THC.

• The typical recommended dosage starts with 0.5-1ml taken sublingually (under the tongue) once or twice daily, holding for 60-90 seconds before swallowing to maximize absorption.
• It's best to start low and go slow to find your optimal dosage, as excessive cannabis and/or cannabinoid use can lead to adverse effects such as dizziness, confusion, dry mouth, and fatigue, as well as more serious side effects like tachycardia, orthostatic hypotension, severe confusion, and paranoia 1.
• The combination of cannabinoids creates what's known as the "entourage effect," where multiple cannabis compounds work together synergistically to enhance therapeutic benefits.
• CBD is known for its anti-inflammatory and anxiolytic properties, CBN may help with sleep and pain relief, while CBC has potential anti-inflammatory and neuroprotective effects.
• However, CBD can interact with certain drugs that are metabolized by the liver, and its use should be carefully considered in patients with liver disease or those taking medications that may interact with CBD, as noted in the 2024 study on the regulatory framework for cannabis 1.
• It's advisable to consult with a healthcare provider before use, especially if you're taking other medications, and to discuss the potential risks and benefits of using this product, including the risk of hepatotoxicity associated with CBD use 1.
• The product should be stored in a cool, dark place, and patients should be aware of the potential for cannabis use disorder and the importance of responsible use, as highlighted in the 2021 study on perioperative pain and addiction interdisciplinary network (PAIN) 1.

From the Research

Humacology "BLACK" 0:250:60:20 Broad Spectrum CBD+CBN+CBC Oil

• The product contains a combination of cannabidiol (CBD), cannabigerol (not mentioned in the product description but related to CBC), cannabinol (CBN), and cannabichromene (CBC) [(2,3,4,5,6)].
• Studies have shown that CBC may have preferential absorption over CBD and THC when administered together 2.
• The therapeutic potential of CBC includes anti-inflammatory, anticonvulsant, antibacterial, and antinociceptive effects 3.
• CBC has been found to exhibit cytotoxic activity against urothelial cell carcinoma, correlated with inhibition of cell migration and cytoskeleton organization, when combined with Δ9-tetrahydrocannabinol (THC) 5.
• CBC, along with CBN and CBG, has been shown to significantly inhibit amyloid β-evoked neurotoxicity and changes in cell morphology in PC12 cells 6.

Pharmacokinetics and Pharmacodynamics

• The pharmacokinetics of CBC have been examined in humans, with a study finding that the Cmax of CBC increased by 1.3-1.8-fold for each twofold increase in dose 2.
• The tmax range of CBC was found to be 1.6-4.3 hours 2.
• The dose of CBD was 18 times higher than the dose of CBC, yet the AUC0-t of CBD was only 6.6-9.8-fold higher than the AUC0-t of CBC 2.

Therapeutic Applications

• CBC has been suggested to have therapeutic potential in the treatment of various diseases, including cancer, neurological disorders, and inflammatory diseases [(3,5,6)].
• Further research is needed to fully understand the therapeutic potential of CBC and its interactions with other cannabinoids 3.